New hope for kidney transplant patients: safer rejection drug on the horizon?
Disease control
Not yet recruiting
This study tests a new medicine called VEL-101 in 120 people receiving a kidney transplant. The goal is to see if VEL-101 is safer and works as well as the standard drug tacrolimus at preventing the body from rejecting the new kidney. Participants will be monitored for side effec…
Phase: PHASE2 • Sponsor: Veloxis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:46 UTC